Photocure ASA (OSE: PHO), a leader in bladder cancer diagnostics, announces the signing and successful completion of its acquisition of Vesica Health, a U.S. established precision diagnostics company advancing AssureMDx, a urine-based molecular test for the early detection of bladder cancer, in a USD 30.5M in total cash + stock transaction designed to expand Photocure’s position across the bladder cancer care continuum. The acquisition of Vesica Health adds a complementary noninvasive molecular diagnostic capability to Photocure’s precision diagnostics bladder cancer portfolio, extending further reach upstream in the patient evaluation pathway.
Read the full article: Photocure ASA to Acquire Vesica Health Inc., Strengthening Leadership in Bladder Cancer Diagnostics //
Source: https://www.prnewswire.com/news-releases/photocure-asa-to-acquire-vesica-health-inc-strengthening-leadership-in-bladder-cancer-diagnostics-302791805.html